Stock Data
$1.70 (0.64%)
Asset Type
Common Stock
Exchange
NYSE
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DRUG MANUFACTURERS - GENERAL
Abbvie Inc. is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and selling a wide range of treatments. Its portfolio includes therapies for autoimmune diseases, various cancers, eye diseases, neurological disorders, and more. Notable products include Humira for autoimmune conditions, Skyrizi and Rinvoq for skin and joint diseases, and Imbruvica for blood cancers. AbbVie also offers products in aesthetics, women's health, and eye care. Founded in 2012 and based in North Chicago, Illinois, AbbVie collaborates with several biotech firms to advance its research in oncology and immunology.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
AbbVie touched a new 52-week high at $265.97, clearing its July 29 peak. The $470 billion pharma has left its spring range near $200 behind.
Nine market leaders hit 52-week highs this week, from Snowflake up 6.4% above its prior peak to Cloudflare edging out gains. Breadth across tech, consumer staples, and auto signals conviction above the tape.
Skyrizi and Rinvoq both cracked 24% growth to power a clean double beat, proving AbbVie's post-Humira franchise can absorb a $10.9 billion acquisition and still deliver operational outperformance.
AbbVie hits a fresh 52-week peak of $263.20, capping a sharp rally that's lifted the stock nearly 43% from January lows.
AbbVie hiked its dividend 5.5% to $1.73 per share, extending a 13-year streak of unbroken payouts even as biosimilar pressure weighs on Humira's top-line growth.
633 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
